Recent study reported in vitro synergistic interaction between two FDA approved drugs, remdesivir (RDV) and ivermectin (IVM) resulting in enhanced antiviral activity against SARS-CoV-2, the causative pathogen of COVID-19. The aim of the current study is comparing the efficacy and safety of combining remdesivir and ivermectin versus using remdesivir alone in patients with severe COVID-19.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
60
(The same remdesivir dose as mentioned + ivermectin 4 tablet (6mg) once daily before meal for four days)
1- Improvement in level of oxygenation
Change in partial pressure of Oxygen and oxygen saturation
Time frame: By arterial blood gas and non-invasive pulse oximeter at date of randomisation, after 1 hour then on daily bases in stable cases till time of patient discharge or death
2- Need for ventilator support
either noninvasive or invasive mechanical ventilation.
Time frame: From date of randomisation to patient discharge from hospital or death.
3- Length of hospital stay
duration of admission in days
Time frame: From date of randomisation to date of patient discharge from hospital or death.
4- Development of complication
allergic reactions, arrhythmia, hepatic toxicity.....
Time frame: From starting to the end of ivermectin therapy (0 to the end of 4th day)
5- Mortality
mortality rates in both groups
Time frame: Through study completion, an average of 3 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.